11 – 20 of 24
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2008
-
Mark
The importance of maintaining FVIII through levels above 1% during prophylactic treatment of hemophilia A: using license study databases to answer key medical questions
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.58-58(
- Contribution to journal › Published meeting abstract
- 2006
-
Mark
Are randomized clinical trials the only truth? Not always
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Inhibitor treatment in haemophilas A and B: Summary statement for the 2006 International Consensus Conference
(
- Contribution to journal › Debate/Note/Editorial
- 2005
-
Mark
Proceedings of the International Haemophilia Prophylaxis Study Group Meeting, November 2003, Montreal, PQ, Canada.
(
- Contribution to journal › Article
- 2004
-
Mark
Optimizing factor prophylaxis for the haemophilia population: where do we stand?
(
- Contribution to journal › Article
- 2003
-
Mark
Consensus perspectives on prophylactic therapy for haemophilia: summary statement.
(
- Contribution to journal › Letter
- 2002
-
Mark
Anti-D (WinRho SD™) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production
(
- Contribution to journal › Article
-
Mark
Unresolved issues in prophylaxis
(
- Contribution to journal › Article
- 2001
-
Mark
Optimal treatments for patients with bleeding disorders.
(
- Contribution to journal › Letter
- 1997
-
Mark
Platelet and immune responses to oral cyclic dexamethasone therapy in childhood chronic immune thrombocytopenic purpura
(
- Contribution to journal › Article